+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk factors of preterm delivery in HIV-infected pregnant women receiving zidovudine for the prevention of perinatal HIV



Risk factors of preterm delivery in HIV-infected pregnant women receiving zidovudine for the prevention of perinatal HIV



Journal of Obstetrics and Gynaecology Research 35(2): 225-233



Several studies have shown that preterm delivery, a primary cause of perinatal mortality and morbidity, is more frequent in HIV-positive women. This study aimed to determine factors associated with prematurity in HIV-infected women and identify risks for which specific interventions could be targeted. Data were prospectively collected in a clinical trial assessing the efficacy of different zidovudine prophylaxis durations for the prevention of perinatal HIV transmission in Thailand. Characteristics associated with prematurity - delivery before 37 weeks--were assessed using univariate and multivariate logistic regression and were subsequently used to identify subgroups of women at risk. Among 979 women, independent prematurity risk factors were: viral load <3.5 or >4.5 log copies/mL; hemoglobin > 11.5 g/dL; weight gain <0.25 kg/week; and body mass index <20 kg/m2. These factors allowed us to define four subgroups with an expected probability of prematurity increasing from 3% to 30%. The two subgroups with the highest expected probability of prematurity were considered to be 'at risk' as opposed to the two lowest (odds ratio = 2.6, 95% confidence interval: 1.7-4.0) and the sensitivity and specificity of the prediction were 51% and 71%, respectively. In this study, four risk factors of preterm delivery were identified allowing the identification of subgroups at increasing risk of prematurity. Adequate nutrition and the provision of highly active antiretroviral therapy during pregnancy as recommended by the World Health Organization for the prevention of perinatal transmission for immunocompromised women in resource-constrained countries may reduce the risk of premature delivery.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055584224

Download citation: RISBibTeXText

PMID: 19708170

DOI: 10.1111/j.1447-0756.2008.00925.x


Related references

Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. AIDS 14(10): 1389-1399, 7 July, 2000

Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. Aids 14(10): 1389-1399, 2000

Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: the impact of social network factors, side effects, and perceived treatment efficacy. Women and Health 42(1): 99-115, 2006

Incidence of and related risk factors on preterm delivery among HIV-infected pregnant women in China. Zhonghua Liu Xing Bing Xue Za Zhi 36(4): 349-353, 2015

Pregnancy outcomes and risk factors for low birth weight and preterm delivery among HIV-infected pregnant women in Guangxi, China. Chinese Medical Journal 125(3): 403-409, 2012

A comparison of maternal anemia between HIV infected pregnant women receiving zidovudine-based and zidovudine-free highly active Antiretroviral therapy (HAART). Journal of the Medical Association of Thailand 97(4): 361-368, 2014

Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. Aids 17(10): 1570-1572, 2003

Inflammatory Markers Related to Microbial Translocation Among HIV-Infected Pregnant Women: A Risk Factor of Preterm Delivery. Journal of Infectious Diseases 213(3): 343-350, 2016

Perinatal zidovudine prophylaxis in HIV type-1-infected pregnant women with thalassaemia carriage in Thailand. Antiviral Therapy 14(1): 117-122, 2009

Economic impact of treating pregnant women with zidovudine in the prevention of perinatal HIV transmission. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS [Author] Eleventh International Conference on AIDS, Vol Two One world: One hope : 378, 1996

Haematological safety of perinatal zidovudine in pregnant HIV-1-infected women in Thailand: secondary analysis of a randomized trial. Plos Clinical Trials 2(4): E11, 2007

Risk Factors for Perinatal Human Immunodeficiency Virus Transmission in Patients Receiving Zidovudine Prophylaxis. Obstetrics & Gynecology 94(6): 897-908, 1999

Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis. Obstetrics & Gynecology 94(6): 897-908, 1999

Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 67(2): 128-135, 2015

Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. Aids 16(4): 625-630, 2002